Morrisey: Reported settlement "sweetheart deal" for Mylan

Published: Nov. 3, 2016 at 12:01 AM EDT
Email This Link
Share on Pinterest
Share on LinkedIn

Attorney General Patrick Morrisey is urging federal and state officials to reject a reported settlement with Mylan Pharmaceuticals over Medicaid reimbursements for the Epipen.

In a letter to U.S. Attorney General Loretta Lynch, Morrisey calls the reported $465 million settlement a "sweetheart deal" for the drug company. The settlement follows the news that the Epipen was incorrectly classified as a generic product under the Medicaid program. The federal government says it's a branded drug, requiring a far higher company rebate.

“The $465 million figure represents a sweetheart deal for Mylan,” Attorney General Morrisey said alleging Mylan may owe as much as $700 million," Morrisey wrote in a press release.

“While Mylan executives and shareholders would be winners, it is a losing proposition for taxpayers who fund Medicaid and the countless families who rely on EpiPen and are beholden to Mylan’s skyrocketing greed,” he continued. “The people are fed up with such arrangements, and frankly, they should be. West Virginia deserves better.”